8P - Plasma cell-free DNA concentration and integrity analysis in patients with chest radiological findings: NSCLC versus non-malignant pathologies

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Adam Szpechcinski
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Szpechcinski1, W. Kupis2, R. Langfort3, J. Zaleska4, K. Maszkowska-Kopij5, R. Struniawski1, M. Skronski1, T. Orlowski2, K. Roszkowski-Sliz4, J. Chorostowska-Wynimko1
  • 1Department Of Genetics And Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 - Warsaw/PL
  • 2Department Of Thoracic Surgery, National Institute of Tuberculosis and Lung Diseases, 01-138 - Warsaw/PL
  • 3Department Of Pathomorphology, National Institute of Tuberculosis and Lung Diseases, 01-138 - Warsaw/PL
  • 4Iii Department Of Lung Diseases, National Institute of Tuberculosis and Lung Diseases, 01-138 - Warsaw/PL
  • 5Outpatient Clinic, National Institute of Tuberculosis and Lung Diseases, 01-138 - Warsaw/PL

Abstract

The quantification of cell-free DNA in plasma (cfDNA) has been repeatedly shown to accurately differentiate NSCLC patients from healthy individuals and indicate the increased cancer risk. However, to be of clinical value, such quantitative assay should also discriminate between lung cancer and non-malignant pathologies presenting similar radiological image. Recently, we demonstrated that increased cfDNA levels in NSCLC patients result from complicated tumor-host interactions, but not from chronic respiratory inflammation itself. In present study we determine cfDNA levels in resectable NSCLC versus non-malignant lung tumors to evaluate the factual clinical utility of cfDNA quantification for early NSCLC detection.